Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **ocular surface glycocalyx** is a complex carbohydrate-rich layer coating the epithelial cells of the cornea and conjunctiva. This structure is primarily composed of membrane-associated mucins (such as **MUC1, MUC4, MUC16, MUC20, MUC21, and MUC22**), proteoglycans, and glycolipids. The mucins form a dense, heavily glycosylated matrix that can reach hundreds of nanometers in thickness and extends from the apical cell surface into the tear film. The glycocalyx is essential for maintaining surface hydration, lubrication, wettability, and acts as both a physical and biochemical barrier, impeding pathogen adhesion and modulating inflammation. It associates with galectin-3 to form a protective galectin-glycan lattice. Breakdown of this structure is implicated in various ocular surface disorders such as **dry eye disease**, infections, allergies, and complications related to systemic diseases. Restoration or protection of the glycocalyx (e.g., via rebamipide) is a therapeutic goal in managing these conditions[1][2][3][4][5][6][7].
Upregulation/restoration of mucin expression, normalization of glycocalyx structure, enhanced barrier and lubrication
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ocular surface glycocalyx.